Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients - results from the prospective 12-month phase of Lanro-Study.

Aim Of The Study: To assess resource utilization and costs of treatment with lanreotide AUTOGEL 120 mg (ATG120) administered as part of routine acromegaly care in Poland.

Material And Methods: A multicentre, non-interventional, observational study on resource utilization in Polish acromegalic patients treated with ATG120 at 4 weeks or extended (> 4 weeks) dosing interval. The study recruited adult acromegalic patients treated medically for ≥ 1 year including at least 3 injections of ATG120.

[Lymphocytic hypophysitis and hypothalamitis-case report].

Lymphocytic hypophysitis is an unusual disorder that nearly exclusively affects women. We present a case of 69 year-old female patient who developed the symptoms of diabetes insipidus and partial insufficiency of the anterior pituitary gland. Magnetic resonance imaging of the brain revealed a mass involving the sella and suprasellar region.

The efficacy of octreotide LAR (long acting release) treatment in patients with somatotropinoma, and mixed pituitary tumours.

Objective: The efficacy of somatostatin analogues in the treatment of acromegaly is not always equal and therefore we wanted to evaluate the efficacy of therapy with octreotide long acting release (LAR) in patients with monohormonal tumours (somatotropinomas) in comparison to individuals with mixed pituitary tumours secreting alpha-subunit.

Method: The 35 acromegalic patients (18 males and 17 females), aged 41.8 +/- 8.

Effect of bromocriptine on cell apoptosis and proliferation in GH3 cell culture.

Objectives: In our study, with the use of GH3 cells line we decided to examine 1) what is the relation between the dose of bromocriptine and the development of apoptosis in GH3 cells 2) whether the induction of apoptosis is accompanied by alterations in bcl-2 and p53 content and 3) whether dibutyryl-cAMP or phorbol esters affect the initiation of apoptosis in GH3 cells.

Results: The current study demonstrated the absence of alterations in GH3 cells incubated for 24 h with bromocriptine at the concentrations of up to 15 micromol/l. Apoptotic and necrotic changes were observed after 48 h incubation with bromocriptine at the concentrations of 25 micromol/l.

[Graves' disease and hyperprolactinemia in a patient with Noonan syndrome neurofibromatosis type 1].

We report the case of a 42-Year-old woman with Recklinghausen disease (neurofibromatosis type 1) and Noonan syndrome who developed Graves' disease. Hyperthyroidism, which had existed for two Years without treatment, led to the discovery of neurofibromatosis type 1. The diagnosis of Graves' disease was confirmed by blood hormone levels, thyroid gland ultrasound, radioisotope scan and thyroid iodine uptake.